Open Heart

Cost-effectiveness analysis of mavacamten for obstructive hypertrophic cardiomyopathy: a perspective from the Chinese healthcare system

Introduction The clinical management of Obstructive Hypertrophic Cardiomyopathy remains challenging, and the phase III ...
2 Minute Medicine

Sodium-glucose cotransporter 2 inhibitors may improve left ventricular diastolic function in hypertrophic cardiomyopathy

Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) were associated with improved left ventricular diastolic function and New York Heart Association (NYHA) class in patients with hypertrophic ...
Nasdaq

Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic ...

Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyo…

HCM First European Launch Expected in Germany in Q2 2026 SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- ...
The American Journal of Managed Care

PapSCAR Prevalence May Predict Cardiac Death in Patients With Dilated Cardiomyopathy

Papillary muscle scarring in DCM patients is associated with higher risks of cardiac death, heart failure, and arrhythmia events. Microvascular dysfunction is a strong predictor of poor prognosis, ...

Cytokinetics, Incorporated: Cytokinetics Announces European Commission Approval of MYQORZO (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic ...

European Commission Approval Based on Results of SEQUOIA-HCM First European Launch Expected in Germany in Q2 2026 SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorpora ...